SCHEMBL2595602

SCHEMBL2595602

C[CH][Si](c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.38
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
ALOX12 P18054 1/20 0.33
ACHE P22303 1/20 0.33
ALDH1A1 P00352 4/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 2/20 0.32
BACE1 P56817 1/20 0.32
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30
AHR P35869 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31054141 0.78 MAPT (0.35) MAPTESR1ESR2LMNATSHR
SCHEMBL940804 0.74 MAPT (0.45) MAPTESR1ESR2LMNATSHR
SCHEMBL28545159 0.71 ALDH1A1 (0.42) MAPTESR1ESR2LMNATSHR
SCHEMBL226240 0.71 ALDH1A1 (0.41) ESR1ESR2TSHRALDH1A1KDM4E
SCHEMBL4625993 0.70 TP53 (0.36) MAPTESR1ESR2LMNATSHR
SCHEMBL8543835 0.70 MAPT (0.38) MAPTESR1ESR2LMNAALDH1A1
SCHEMBL8549786 0.69 MAPT (0.33) MAPTESR1ESR2TSHRALDH1A1
SCHEMBL6550222 0.67 MAPT (0.36) MAPTESR1ESR2
SCHEMBL28638586 0.67 MAPT (0.35) MAPTESR1ESR2LMNATSHR
SCHEMBL8002913 0.67 ALDH1A1 (0.32) ESR1ESR2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100323000-A1 METHOD AND PROCESS FOR PREPARING CARDIOLIPIN NEOPHARM, INC. (US) 2010-12-23 US claimed
US-6953850-B1 Protecting groups for carbohydrate synthesis ALCHEMIA PTY. LTD. (AU) 2005-10-11 US claimed
US-11814484-B2 Modified filler particles and silicone compositions comprising the same MOMENTIVE PERFORMANCE MATERIALS GMBH 2023-11-14 US disclosed
CN-108026372-B Modified filler particles and silicone compositions containing the same 莫门蒂夫性能材料有限公司 2022-03-15 CN disclosed
US-20220002492-A1 MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) 2022-01-06 US disclosed
US-11015024-B2 Modified filler particles and silicone compositions comprising the same MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2021-05-25 US disclosed
US-20180208718-A1 MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME MOMENTIVE PERFORMANCE MATERIALS INC. 2018-07-26 US disclosed
EP-3325557-A1 MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME Momentive Performance Materials GmbH (DE) 2018-05-30 EP disclosed
WO-2017012715-A1 MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) 2017-01-26 WO disclosed
EP-2601204-A2 MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM Isis Pharmaceuticals, Inc. (US) 2013-06-12 EP disclosed
WO-2011139702-A2 MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 2011-11-10 WO disclosed
EP-0592534-A4 SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM ABBOTT LAB (US) 1994-07-06 EP disclosed
EP-0592534-A1 SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM ABBOTT LABORATORIES (US) 1994-04-20 EP disclosed
EP-0591344-A1 A PROCESS FOR SYNTHESIS OF SILYL ALCOHOLS ABBOTT LABORATORIES (US) 1994-04-13 EP disclosed
EP-0591302-A1 SUBSTITUTED SILYL ALCOHOLS ABBOTT LABORATORIES (US) 1994-04-13 EP disclosed
WO-1992022561-A1 A PROCESS FOR SYNTHESIS OF SILYL ALCOHOLS ABBOTT LABORATORIES (US) 1992-12-23 WO disclosed
WO-1992022557-A1 SUBSTITUTED SILYL ALCOHOLS ABBOTT LABORATORIES (US) 1992-12-23 WO disclosed
WO-1992021689-A1 SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM ABBOTT LABORATORIES (US) 1992-12-10 WO disclosed
US-5159095-A Reagant for phosphorylating oligonucleotides ABBOTT LABORATORIES (US) 1992-10-27 US disclosed
US-5113005-A Hydrosilation ABBOTT LABORATORIES (US) 1992-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100323000-A1 METHOD AND PROCESS FOR PREPARING CARDIOLIPIN PHOSPHO1, SGMS1, SGMS2 MAPT 4674/4885ESR1 4835/4885ESR2 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.